Inhaled colistin in elderly patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa bronchial infection;Tratamiento inhalado con colistina a largo plazo en pacientes ancianos con infección crónica por Pseudomonas aeruginosa y bronquiectasias

Revista Espanola de Geriatria y Gerontologia

Volumn 50, Issue 3, 2015, Pages 111-115

  Tabernero Huguet, Eva ^a   Gil Alaña, Pilar ^a   Alkiza Basañez, Ramón ^a   Hernández Gil, Anibal ^a   Garros Garay, Javier ^a   Artola Igarza, Juan Luis ^b  

^a Hospital de Santa Marina   (Spain)

^b HOSPITAL DE GALDAKAO   (Spain)

Author keywords

Bronchiectasis; Elderly; Nebulized antibiotics

Indexed keywords

COLISTIN; ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BRONCHIECTASIS; BRONCHITIS; CHARLSON COMORBIDITY INDEX; CHRONIC DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYSTIC FIBROSIS; DEMOGRAPHY; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; LUNG FUNCTION; OPEN STUDY; PHYSIOTHERAPY; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; SPUTUM ANALYSIS; UNSPECIFIED SIDE EFFECT; BRONCHIAL DISEASES; COMPLICATION; CONTROLLED CLINICAL TRIAL; FEMALE; INHALATIONAL DRUG ADMINISTRATION; MALE; MICROBIOLOGY; PSEUDOMONAS INFECTIONS;

ADMINISTRATION, INHALATION; AGED; ANTI-BACTERIAL AGENTS; BRONCHIAL DISEASES; BRONCHIECTASIS; CHRONIC DISEASE; COLISTIN; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84929046390     PISSN: 0211139X     EISSN: 15781747     Source Type: Journal    
DOI: 10.1016/j.regg.2014.09.005     Document Type: Article

References (26)

1. Nicotra Mb, Rivera M., Dale A.M., Shepherd R., Carter R. Clinical, pathophysiology and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995, 108:955-961.
2. Weycker D., Edelsberg J., Oster G., Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005, 12:205-209.
3. McShane P.J., Naureckas E.T., Tino G., Strek M.E. Non cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2013, 188:647-656.
4. Seitz A., Olivier K., Steiner C., Montes de Oca R., Holland S., Prevots R. Trends and burden of bronchiectasis associated hospitalizations in the United States 1993-2006. Chest 2010, 138:944-949.
5. Whitters D., Stockley R.A. Bronchiectasis in older patients with COPD: prevalence, diagnosis and therapeutic management. Drugs Aging 2013, 30:215-225.
6. Martínez-García M.A., de la Rosa Carrillo D., Soler-Cataluña J.J., Donat-Sanz Y., Serra P.C., Lerma M.A., et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 187:823-831.
7. Loebinger M.R., Wells A.U., Hansell D.M., Chinyanganya N., Devaraj A., Meister M. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009, 34:843-849.
8. Scheinberg P., Shore B.E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005, 127:1420-1426.
9. Barker A., Couch L., Fiel B., Gottfried M., Ilowite J., Meyer K., et al. Tobramycin solution for inhalation reduces sputum pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000, 162:481-485.
10. Steinfort D.P., Steinfort C. Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Internal Medicine Journal 2007, 37:495-498.
11. Drobnic M.E., Suñé P., Montoro J.B., Ferrer A., Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005, 39:39-44.
12. Dhar R., Anwar G.A., Bourke S.C., Doherty L., Middleton P., Ward C., et al. Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonized with Pseudomonas aeruginosa. Thorax 2010, 65:553.
13. Serisier D., Bilton D., De Soyza A., Thompson P., Kolbe J., Greville H., et al. Inhaled dual release liposomal ciprofloxacin in non cystic fibrosis bronchiectasis (ORBIT 2) a randomized, double blind placebo-controlled trial. Thorax 2013, 68:812-817.
14. Wilson R., Welte T., Polverino E., de Soyza A., Greville H., O'Donnell A., et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013, 41:1107-1115.
15. Murray M.P., Govan J.R., Doherty C.J., Simpson A.J., Wilkinson T.S., Chalmers J.D., et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011, 183:491-499.
16. Antoniu S.A., Trofor A.C. Inhaled gentamicin in non-cystic fibrosis bronchiectasis: effects of long-term therapy. Expert Opin Pharmacother 2011, 12:1191-1194.
17. White L., Mirrani G., Grover M., Rollason J., Malin A., Suntharalingam J. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med 2012, 106:356-360.
18. Orriols R., Roig J., Ferrer J., Sampol G., Rosell A., Ferrer A., et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med. 1999, 93:476-480.
19. Hill A., Welham S., Reid K., Bucknall C.E. British Thoracic Society national bronchiectasis audit 2010 and 2011. Thorax 2012, 67:928-930.
20. Vendrell M., de Gracia J., Olveira C., Martínez M.A., Girón R., Luis Máiz, et al. Diagnóstico y tratamiento de las bronquiectasias. Normativa Separ. Arch Bronconeumol 2008, 44:629-640.
21. Pasteur M.C., Bilton D., Hill A.T. BTS guideline for non-CF bronchiectasis. Thorax 2010, 65(s):1-58.
22. Haworth C.S., Foweraker J.E., Wilkinson P., Kenyon R.F., Bilton D. Inhaled colistin in patients with non CF bronchiectasis and chronic pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014, 189:975-982.
23. Baker A., Donnell O., Thomson A., Flume P., Ruiz P., Gracia J.J. Two phase 3 placebo-controlled trials of aztreonam lysine for inhalation (AZLI) for non cystic fibrosis bronchiectasis (NCFB). ERS 2013, (S) P 4136.
24. Evans D.J., Bara A.I., Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev. 2007, CD001392 DOI: 10.1002/14651858.CD001392 pub2.
25. Martinez-Garcia M.A., de Gracia J., Vendrell Relat M., Giron R.M., Maiz-Carro L., de la Rosa Carrilo D., et al. Multidimensional approach to non-cystic fibrosis bronchiectasis. The FACED Score. Eur Respir J 2014, 43:1357-1367.
26. Chalmers J., Goeminne P., Aliberti S., McDonnell M., Lonni S., Davidson J., et al. The bronchiectasis severity index. An international derivation and validation study. Am J Crit Care Med 2014, 189:576-585.